Sulfone reverse hydroxamates as matrix metalloproteinase inhibitors

Bibliography

• NAGASE H, WOESSNER JF: Matrix metalloproteinases. J. Biol. Chem. (1999) 274:21491–21494.
   PubMed Web of Science ®Google Scholar
• SHAPIRO SD: Matrix metalloproteinases degradation of ex tracellular matrix: biological consequences. Curr. Opin. Cell Biol. (1998) 1 0 :602–608.
   Google Scholar
• MCCAWLEY LJ, MATRISIAN LM: Matrix metalloprote-inases: multifunctional contributors to tumor progres-sion. Mol. Med. Today (2000) 6:149–156.
   PubMedGoogle Scholar
• NELSON AR, FINGLETON B, ROTHENBERG ML,MATRISIAN LM: Matrix metalloproteinases: biologic activity and clinical implications. J Clin. Oncol. (2000) 18:1135–1149.
   PubMed Web of Science ®Google Scholar
• WHITTAKER M, FLOYD CD, BROWN P, GEARING AJH: and therapeutic application of matrix metallo-proteinase inhibitors. Chem. Rev. (1999) 99:2735–2776.
   PubMed Web of Science ®Google Scholar
• ••Excellent review on MMPIs, covering both design andpharmacological effects.
   Google Scholar
• BABINE RE, BENDER SL: Molecular recognition of-ligand complexes: Applications to drug design. Chem. Rev. (1997) 97:1359–1472.
   PubMed Web of Science ®Google Scholar
• •Discusses the specifity pockets of MMPs, their catalytic mechanism and critical interaction with MMPIs.
   Google Scholar
• MICHAELIDES MR, CURTIN ML: Recent advances in metalloproteinase inhibitors research. Curr. Pharm. Des. (1999) 5:787–819.
   PubMed Web of Science ®Google Scholar
• ••Review effectively highlighting the different chemicaltemplates.
   Google Scholar
• BECKETT RP, WHITTAKER M: Matrix metalloproteinase 1998. Exp. Opin. Ther. Patents (1998) 8:259–282.
   Web of Science ®Google Scholar
• ••Review with comprehensive analysis of the patent literature.
   Google Scholar
• DE B, NATCHUS MG, CHENG M et al.: The next genera-tion of MNIP inhibitors. Design and synthesis. Ann. NY Acad. Sci. (1999) 878:40–60.
   PubMed Web of Science ®Google Scholar
• BROWN PD: Ongoing trials with matrix metalloprote-inase inhibitors. Exp. Opin. Invest. Drugs (2000) 9:2167–2177.
   PubMed Web of Science ®Google Scholar
• ••Most updated review of clinical results with MMPIs.
   Google Scholar
• CURTIN ML, GARLAND RB, DAVIDSEN SK et al.: Broad matrix metalloproteinase inhibitors with P1 gem-disubstitution. Bioorg. Med. Chem. Lett. (1998) 8:1443–1448.
   PubMedGoogle Scholar
• SHEPPARD GS, FLORJANCIC AS, GIESLER JR et al.: Aryl ketones as novel replacements for the C-terminal amide bond of succinyl hydroxamate MM1" inhibitors. Bioorg. Med. Chem. Lett. (1998) 8:3251–3256.
   PubMedGoogle Scholar
• HAJDUK PJ, SHEPPARD G, NETTESHEIM DG et al.: Discovery of nonpeptide inhibitors of stromelysin using SAR by NMR. J. Am. Chem. Soc. (19 9 7) 1 1 9:5818-5827.
   Google Scholar
• OLEJNICZAK ET, HAJDUK PJ, MARCOTTE PA et al.: Stromelysin inhibitors designed from weakly bound fragments: effects of linking and coop erativity. j. Am. Chem. Soc. (1997) 1 1 9:5828–5832.
   Google Scholar
• JOHNSON WH, ROBERTS NA, BORKAKOTI N: Collage-nase inhibitors: their design and potential therapeutic use. J. Enzyme Inhibition (1987) 2:1–22.
   Google Scholar
• CASTELHANO AL, BILLEDEAU R, DEWDNEY N et al.: Novel indolactam-based inhibitors of matrix metallo-proteinases. Bioorg. Med. Chem. Lett. (1995) 5:1415–1420.
   Web of Science ®Google Scholar
• Reverse hydroxamates derivatives as metalloprotease inhibitors. Exp. Opin. Ther. Patents (1999) 9:1575–1578.
   Google Scholar
• CARTY TJ, LOPRESTI-MORROW LL, MITCHELL PG, MCNIFF PA, MCCLURE KF: New insight into disintegrin metalloproteases. Inflamm. Res. (1999) 48:229–231.
   PubMedGoogle Scholar
• CONWAY JG, TREXLER SJ, WAKEFIELD JA et al.: Effect of matrix metalloproteinase inhibitors on tumor growth and spontaneous metastasis. an. Exp. Metastasis (1996) 14:115–124.
   PubMed Web of Science ®Google Scholar
• ZOOK SE, BENDER SL: MMP inhibitors: asymmetric synthesis of N-hydroxy-N-formyl dip ep tides via (R)-1-benzyloxy-3-ally1-2-azetidinone. 35th National Organic Chemistry Symposium. San Antonio, USA (1997).
   Google Scholar
• CRAWLEY GC: Modulation of TNF-a through inhibition of TNF-a converting enzyme. 10th RSC-SCI Medicinal Chemistry Symposium. Cambridge, UK (1999).
   Google Scholar
• JACKSON WP, ISLIP PJ, KNEEN G, PUGH A, WATES PJ: acids as potent, selective, orally active 5-lipoxygenase inhibitors. J Med. Chem. (1988) 31:499–500.
   PubMed Web of Science ®Google Scholar
• SALMON JA, JACKSON WP, Garland LG: Inhibition of 5-lipoxygenase: development of hydroxamic acids and hydroxyureas as potential therapeutic agents. Adv. Prostaglandin Tromboxane Res. (1990) 21:109–112.
   Google Scholar
• BROOKS CDW, SUMMERS JB: Modulators of leukotriene biosynthesis and receptor activation. J Med. Chem. (1996) 39:2629–2654.
   PubMed Web of Science ®Google Scholar
• MILLAR A, BROWN P: 360 Patient meta-analysis of studies of marimastat. A novel matrix metalloprote-inase inhibitor. Ann. Oncol. (1966) 7 (Suppl. 5):123.
   Google Scholar
• •First report of the musculoskeletal syndrome elicited in humans after prolonged administration of marimastat.
   Google Scholar
• WOJTOWICZ-PRAGA S, TORRI J, JOHNSON M et al.: Phase trial of marimastat, a novel matrix metalloproteinase inhibitor administered orally to patients with lung cancer. J. Clin. Oncof (1998) 16:2150–2156.
   PubMed Web of Science ®Google Scholar
• •States the musculoskeletal syndrome elicited in humans after prolonged administration of marimastat. To a lesser degree, this side effect was more recently admitted for other MMPIs, including CGS-27023A, prinomastat and BMS–275291.
   Google Scholar
• DERYUGINA El, BOURDON MA, REISFELD RA, STRONGIN: Remodeling of collagen matrix by human tumor cells requires activation and cell surface association of matrix metalloproteinase-2. Cancer Res. (1998) 58:3743–3750.
   PubMed Web of Science ®Google Scholar
• ITOH T, TANIOKA M, YOSHIDA T, YOSHIOKA T, NISHIMOTO H, ITOHARA S: Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res. (1998) 58:1048–1051.
   PubMed Web of Science ®Google Scholar
• MARSHALL JL, BAIDAS S, BHARGAVA P, RIZVI N: Matrix metalloproteinase inhibitors in cancer: an update. IDrugs (2000) 3:518–524.
   PubMedGoogle Scholar
• SCATENA R: Prinomastat, a hydroxamate-based matrix metalloproteinase inhibitor. A novel pharmacological approach for tissue remodelling-related diseases. Exp. Opin. Invest. Drugs (2000) 9:2159–2165.
   PubMedGoogle Scholar